News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pulmokine Awarded $1.5 Million Stage B VITA Contract To Advance Inhaled Kinase Inhibitors For Pulmonary Arterial Hypertension



3/27/2014 9:03:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Rensselaer, NY, March 27, 2014 (GLOBE NEWSWIRE) -- Pulmokine announced it has been awarded a Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). Proceeds from the contract will be used to develop an inhaled PDGF receptor kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The VITA contract will fund the performance of studies that will support an Investigational New Drug (IND) application to be submitted to the FDA. The potential value of the award is approximately $1.5 Million over three years.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES